Board of directors

Anker Lundemose, MD PhD

Chair

CEO at Mission Therapeutics focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.

Roderick Verhelst, PhD

Bioqube Ventures

Principal at Bioqube Ventures focusing on sourcing, financing and developing innovative therapeutic assets and technologies.

Jeroen Bakker, PhD

Novo Seeds

Principal at Novo Holdings and part of the Novo Seeds team focusing early-stage financing and development of strong and competitive companies.

Nick Stub Laursen, PhD

Head of Discovery & Co-founder

Nick has extensive experience in antibody characterization and has worked within the field of complement research for more than 15 years.

Mikkel Wandahl Pedersen, PhD

CEO & CSO

Seasoned R&D executive and scientific leader with over two decades of experience in antibody development from immuno-oncology and autoimmune disease drug discovery programs.

Eva Van Overmeire, PhD

Senior Investment Manager

Senior Investment Manager at Korys focusing on investments in companies developing science-based solutions that prevent or treat diseases.

Janine Schuurman, PhD

Antibody enthusiast and molecular Immunologist

Formerly served as SVP Antibody Research and Technology at Genmab. Pioneered IgG4 biology and IgG1-complement interactions leading to groundbreaking insights in antibody biology. Co-inventor of numerous therapeutic antibodies, including FDA-approved RYBREVANT® (amivantamab) and EPKINLY® (epcoritamab). Also co-inventor of the bispecific antibody platform DuoBody® and effector function-enhanced HexaBody® and HexElect® technologies.

Scientific Advisory Board

Janine Schuurman, PhD

Molecular immunologist

Janine is a molecular immunologist who has contributed to six FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab’s DuoBody bispecific antibody platform. She spent 22 years at Genmab, most recently as Senior Vice President, Head of Antibody Research and Technology, propelling the discovery and development of investigational therapies to treat cancer and other diseases. Besides serving as an independent biotech consultant providing expert advice to a number of life sciences companies, Janine also serves as board member and President of The Antibody Society.

Gavin Thurston, PhD

Biotech scientist in oncology and vascular biology

Gavin is a highly experienced R&D executive and scientific leader with over 20 years of experience in oncology research. He previously served as Senior Vice President of Oncology Research at Regeneron, where he played a pivotal role in the successful clinical development of LIBTAYO® and the ongoing late-stage clinical testing of seven other antibodies and bispecific antibodies. Following his time at Regeneron, Dr Thurston has been involved in a number of consultancy projects with antibody therapeutic companies.

Paul W.H.I. Parren, PhD

Professor of Molecular Immunology

Paul is a molecular immunologist who has contributed to nine FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab’s DuoBody bispecific antibody platform. He has spent over 25 years translating antibody knowledge into innovative therapies including 15 years at Genmab, where he headed preclinical R&D. More recently he was head of R&D at LAVA Therapeutics NV, which obtained a NASDAQ listing during his five-year tenure. He currently serves as Professor of Molecular Immunology at Leiden University Medical Centre in The Netherlands, is chairman of the board of The Antibody Society, provides expert advice and is a co-founder and CSO of Gyes BV and its two spin-out companies.

Susan Kalled, PhD

Immunologist

Susan is an immunologist with over 25 years of experience spanning early discovery research, clinical drug development and strategic partnerships in the areas of autoimmunity & inflammation, rare diseases and immuno-oncology. Previously she was CSO at Dianthus Therapeutics and Compass Therapeutics. As Vice President of Biology at Q32 Bio, Kalled established the founding research team and played a key role in shaping the company’s complement and immunology-focused pipeline. She has also held a number of leadership positions at Biogen and Shire, driving scientific strategy. She currently serves as a scientific strategist and advisor to both early start-ups and established companies.

Esper Boel, PhD

Molecular biologist

Esper is a molecular biologist with 40 years of experience in international biopharmaceutical R&D. He spent 34 years at Novo Nordisk, most recently, as Corporate Vice President and Head of Biotechnology. During this time, he was responsible for building and heading a 240+ employee international protein-biotechnology organisation and he established the first international biopharmaceutical R&D centre in Beijing, China. Following his time at Novo Nordisk, he has served as member of executive teams, boards and as senior advisor for a number of high-profile immunology-based companies.